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foods on blood levels of selenium and
selenoprotein P in a randomized dietary
intervention study in Danes
Tine Iskov Kopp1,2,3,5* , Malene Outzen1,2, Anja Olsen2, Ulla Vogel4 and Gitte Ravn-Haren1
Abstract
Background: Selenium is an essential trace element and is suggested to play a role in the etiology of a number of
chronic diseases. Genetic variation in genes encoding selenoproteins, such as selenoprotein P and the glutathione
peroxidases, may affect selenium status and, thus, individual susceptibility to some chronic diseases. In the present
study, we aimed to (1) investigate the effect of mussel and fish intake on glutathione peroxidase enzyme activity
and (2) examine whether single nucleotide polymorphisms in the GPX1, GPX4, and SELENOP genes modify the effect
of mussel and fish intake for 26 weeks on whole blood selenium, plasma selenoprotein P concentrations, and
erythrocyte GPX enzyme activity in a randomized intervention trial in Denmark.
Results: CC homozygotes of the SELENOP/rs3877899 polymorphism who consumed 1000 g fish and mussels per
week for 26 consecutive weeks had higher levels of both selenoprotein P (difference between means − 4.68 ng/mL
(95% CI − 8.49, − 0.871)) and whole blood selenium (difference between means − 5.76 (95% CI − 12.5, 1.01))
compared to fish and mussel consuming T-allele carriers although the effect in whole blood selenium
concentration was not statistically significant.
Conclusions: Our study indicates that genetically determined variation in SELENOP leads to different responses in
expression of selenoproteins following consumption of selenium-rich foods. This study also emphasizes the importance
of taking individual aspects such as genotypes into consideration when assessing risk in public health recommendations.
Keywords: Selenium, Selenoprotein P, Glutathione peroxidase, Dietary intervention, Randomized, Gene-diet interaction,
SELENOP, GPX1, GPX4, Single nucleotide polymorphisms
Background
Selenium is an essential trace element and is suggested to
play a role in the etiology of a number of chronic diseases
[9, 37]. Several factors can affect selenium status; these
include exposure to selenium through diet or dietary
supplements [32, 33, 35] and lifestyle factors such as body
mass index (BMI) and smoking [6]. Furthermore, genetic
variation has been proposed to influence selenium status
of the individual [14].
Most of the biological functions of selenium are carried
out by selenoproteins [30]. Among the best characterized
selenoproteins with essential functions are selenoprotein P
and the glutathione peroxidases (GPX), including GPX1
and GPX4 [30]. Besides functioning as storage and trans-
port protein for selenium, some studies suggest that sele-
noprotein P is involved in the antioxidant defense which
also comprises the glutathione peroxidases [40]. These
antioxidant selenoenzymes detoxify a range of hydroperox-
ides, including lipid and phospholipid hydroperoxides,
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thereby ensuring a reducing environment and protecting
cell components such as proteins, lipids, and DNA from
oxidative damage [36]. Nutritional deficiency in selenium
results in decreased selenoprotein concentrations and a
compromised enzymatic antioxidant defense. Selenium
supplementation is known to affect selenoprotein expres-
sion in a hierarchical manner. GPX4 ranks higher in the
hierarchy of selenoproteins compared to GPX1 which is
much more responsive to both selenium depletion and
repletion [2, 4]. Humans differ in their ability to metabolize
selenium and respond differently to selenium supplemen-
tation. These differences are likely to be due to genetic
variation in selenoprotein genes [6, 16]. Specifically, func-
tional single nucleotide polymorphisms (SNPs) in GPX1
(encoding GPX1), GPX4 (encoding GPX4), and SELENOP
(encoding SELENOP) have been shown to affect blood
selenium or selenoprotein levels in response to supplemen-
tation [19, 20, 23]. The GPX1/rs1050450 polymorphism is
a Pro to Leu substitution at position 197 [10] which results
in reduced enzyme activity [16, 34] and higher DNA dam-
age levels [25]. GPX1/rs1050450 has also been associated
with risk of several diseases, including lung [31, 39], breast
[8, 21, 34], and prostate cancer [3, 43]; peripheral
neuropathy [45]; coronary heart diseases [26, 50]; septic
shock [18]; and mortality [42], and correlation between
GPX1 activity and serum selenium concentration has been
reported for this polymorphism [16]. GPX4/rs713041
affects protein binding to the 3′-untranslated region close
to a selenocysteine insertion sequence required for seleno-
protein synthesis [20, 48] and has been associated with
decreased GPX enzyme activity [21], risk of colorectal
cancer [43], and mortality [47]. SELENOP/rs3877899
causes an Ala to Thr amino acid substitution at position
234, and SELENOP/rs7579 is located in the 3′-untrans-
lated region of SELENOP mRNA, where it causes a G to A
base change [19]. Both SELENOP polymorphisms lead to
alterations in selenium metabolism by changing the pro-
portion of the 60-kDa isoform of selenoprotein P [23].
They have been shown to affect selenium and selenopro-
tein P blood concentrations after supplementation with
selenium [19] and have also been associated with risk of
various diseases, including breast [21], prostate [7, 13, 43],
and colorectal cancer [22, 23] and aortic aneurisms
[44].Taken together, these results point to a regulatory role
of these polymorphisms in the expression of the encoded
selenoproteins. However, it is not clear whether this is also
the case at selenium intakes that are dietary feasible.
In a previous randomized dietary intervention with fish
and mussels in middle-aged Danes, we found increased
whole blood selenium and plasma selenoprotein P concen-
trations among healthy participants after 26 weeks’ inter-
vention [28]. We hypothesized that SELENOP gene
variations modify the effect of increased dietary selenium
intake on markers of selenium status. Thus, in the present
paper, we aimed to (1) investigate the effect of mussel and
fish intake on GPX enzyme activity and (2) examine
whether SNPs in the GPX1, GPX4, and SELENOP genes
modify the effect of the intervention with mussel and fish
on whole blood selenium, plasma selenoprotein P concen-
trations, and erythrocyte GPX enzyme activity in the same
study population of healthy middle-aged Danish men and
women.
Methods
Study population
This study is based on data from a randomized dietary
intervention study with the primary aim of studying the
influence of increased intake of fish and mussels on
blood selenium levels. The study design and methods
are described in details elsewhere [28].
The study took place in the northern part of Jutland,
Denmark, from September 2010 to March 2011 as a
26-week randomized dietary intervention study with two
parallel groups including healthy middle-aged participants.
Eligibility for randomization was determined by potential
participants completing a questionnaire 3 months before
baseline measurements on lifestyle, diet, and health status.
The goal was to recruit a total of 100 men and women
aged 50–74 years with a BMI of 18.5–28 kg/m2 based on
a power calculation where a minimum detectable differ-
ence of 10 ng/mL (SD = 10) or 30 ng/mL (SD = 10) in sel-
enium concentration between groups with a statistical
power of 87 or 99%, respectively, was allowed [29]. The
exclusion criteria included current smoking, intake of
dietary supplements containing selenium 3 months before
baseline measurements, frequent intake of fish and shell-
fish (> 300 g/week), excessive intake of alcohol (according
to the official Danish guidelines at study recruitment:
women > 14 units of alcohol/week, men > 21 units of alco-
hol/week), strenuous exercise (> 10 h/week), severe
chronic disease, and frequent use of specified medication
(including diabetic medicine, anticoagulant medicine, and
medication for heart disease), or a cancer diagnosis within
the past 5 years. Study participants were requested to
inform the investigators of any changes regarding disease
or medication occurring during the study. Study partici-
pants were recruited through local media, including news-
paper advertisements. Of the 102 men and women
enrolled in the study, 83 completed the intervention. Flow
chart of the participants is illustrated in Additional file 1
as previously published [28].
Dietary intervention
Participants in the intervention group were provided
with 1000 g raw fish and raw or processed mussels (por-
tion size of 200 g; five portions/week) once a week for
26 weeks. This amount corresponds to an intake of
approximately 50.3 μg selenium/day (based on data from
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the Danish Food Composition Databank) [41]. The
participants received four or five different types of fish
per week. Diversity in the type of fish provided was
prioritized to ensure variation and thereby optimize
compliance. The participants were allowed to consume
other meals containing fish or shellfish besides the
experimental foods. The intervention diet has been
described in detail elsewhere [28].
To monitor their compliance, the participants were
provided with a self-monitoring record and kitchen
scales to weigh the amount of received fish and mussels
(prepared or raw) not consumed during the study
period. At study initiation, participants were instructed
on how to complete the self-monitoring record. Compli-
ance was calculated as total received amount—not
ingested amount after preparation)/by total received
amount; the median of ingested proportion was 99% of
the received fish and mussels [28].
Participants in the control group received no interven-
tion and were advised to maintain their habitual diets.
Data collection
Non-fasting blood samples were collected three times
(weeks 0, 13, and 26) from each participant during the
study. Blood samples were drawn in K2-EDTA-coated
blood drawing tubes as whole blood samples or blood
samples that were separated into plasma, erythrocytes, and
buffy coat by centrifugation. All samples were stored at −
80 °C until analysis.
Biochemical analyses
Whole blood selenium analyses were conducted using
an ELAN 6100 DRC inductively coupled plasma-mass
spectrometer (ICP-MS) in accordance with a method
described in detail in [15]. The concentration of sele-
noprotein P in plasma was determined using its se-
lective retention by heparin-affinity high-performance
liquid chromatography (HPLC) and online detection
by ICP-DRC-MS of selenium eluting from the HPLC
column. In addition to determining selenoprotein P,
the concentration of total selenium in plasma was
also quantified by isotope dilution on the basis of the
area under the complete chromatogram. However,
even though the results seemed accurate (that is, the
values obtained from plasma selenium did not deviate
from certified values from reference material), the
method used to determine plasma selenium in this
way was less precise than that used to determine
selenium in whole blood. Therefore, the baseline
plasma selenium concentration was used only for
comparison with other studies measuring plasma sel-
enium in healthy populations. The analysis methods
have been described in details previously [28].
GPX enzyme activities were spectrophotometrically
assayed in erythrocyte lysates on a Pentra 400 (Horiba
ABX, Montpellier, France), using t-butylhydroperoxide
as substrate according to the method described by
Wheeler et al. [49]. GPX activities were related to the
amount of hemoglobin (Hb) in the lysates. Hb con-
tent was determined using a commercially available
kit (Randox Ardmore, UK, cat. no HG 980). Samples
from each individual were run in the same batch in
random order to decrease variation, and a control
sample was included for every 15th sample. Intra-
and inter-day variations were < 5 and < 10%,
respectively.
SNP selection and genotyping
The following polymorphisms were selected based on
their known functionality and association with disease:
GPX1/rs1050450, GPX4/rs713041, SELENOP/rs3877899,
and SELENOP/rs7579.
DNA from the participants was extracted from frozen
lymphocytes as described [24]. Genotypes were deter-
mined using RT-PCR and allelic discrimination on ABI
7900HT instruments (Applied Biosystems, Nærum,
Denmark). Generally, 40–200 ng/μl DNA was obtained
and 10 ng of DNA was genotyped in 5 μl containing 50%
2 × Mastermix (Applied Biosystems, Nærum, Denmark),
100 nM probes, and 900 nM primers.
GPX1/rs1050450: primers: F: 5′-TGT GCC CCC TAC
GCA GGT ACA-3′, R: 5′-CCC CCG AGA CAG CAG
CA-3′ (TAGCopenhagen, Copenhagen, Denmark), T-allele:
5′-FAM-CTG TCT CAA GGG CTC AGC TGT-MGB-3′,
C-allele: 5′-VIC-CTG TCT CAA GGG CCC AGC TGT-
MGB-3′ (Applied Biosystems, Nærum, Denmark).
GPX4/rs713041: primers: F: 5′-CCC ACT ATT TCT AG
C TCC ACA AGT G-3′, R: 5′-GTC ATG AGT GCC GGT
GGA A-3′ (TAGCopenhagen, Copenhagen, Denmark),
T-allele: 5′-FAM-ACG CCC TTG GAG C-MGB-3′, C-
allele: 5′-VIC-ACG CCC TCG GAG C-MGB-3′ (Applied
Biosystems, Nærum, Denmark).
SELENOP/rs3877899 was determined using the
TaqMan® Pre-designed SNP genotyping; assay ID C_2
841533_10, respectively (Applied Biosystems, Nærum,
Denmark).
SELENOP/rs7579: primers: F: 5′-CAA AAA AGT GA
G AAT GAC CTT CAA ACT-3′, R: 5′-ATG CTG GAA
ATG AAA TTG TGT CTA GA-3′ (TAGCopenhagen,
Copenhagen, Denmark), G-allele: 5′-FAM-AAA ATA G
GA CAT ACT CCC C-MGB-3′, A-allele: 5′-VIC-AAA T
AG AAC ATA CTC CCC AAT T-MGB-3′ (Applied
Biosystems, Nærum, Denmark).
All samples were determined as duplicates with known
positive controls (three for each genotype) and three
negative controls containing Milli Q water. All dupli-
cates yielded 100% identical genotypes.
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Statistical methods
The statistical analysis was based on all available observa-
tions. Participants who were randomized into a group, but
did not attend the baseline appointment (week 0), were
excluded. Baseline characteristics are presented as either
number with its percentage and medians with 5th and
95th percentiles for each study group. For the polymor-
phisms, minor allele frequencies are also presented. Outly-
ing observations were identified from visual inspection of
the data (correlation plots of week 0 vs. week 13 and week
0 vs. week 26). Deviation from Hardy–Weinberg equilib-
rium was assessed using a chi-square test.
Linear multiple regression analysis was applied to
evaluate the intervention effect on erythrocyte GPX en-
zyme activity. Within the two groups, mean changes
(weeks 0–13, weeks 0–26) and the difference between
the groups’ mean changes (weeks 0–26) were calculated
from the linear multiple regression. All values of GPX
enzyme activity were log-transformed to correct for
right-skewed distribution.
To examine the association between mean concentra-
tions of whole blood selenium, plasma selenoprotein P or
erythrocyte GPX enzyme activity according to genotype at
baseline, week 13 and week 26, respectively, a linear mul-
tiple regression analysis was applied using least square
means adjusted for baseline concentrations of whole blood
selenium, plasma selenoprotein P, or erythrocyte GPX en-
zyme activity, respectively. Adjustment for baseline level
was done to eliminate baseline levels’ influence on the
effect of the SNPs. In order to increase the statistical
power, heterozygote variant allele and homozygote variant
allele carriers were pooled in the analyses.
Moreover, we examined whether sex, BMI, and age
modified the relationship between intervention
outcomes and the polymorphisms. An interaction term
between sex, BMI, and age, respectively, and the studied
polymorphisms was therefore included in the model.
A mixed-model, repeated-measures analysis of variance
(ANOVA) was used to determine the within-subject effect
between genotype and erythrocyte GPX enzyme activity,
whole blood selenium, or plasma selenoprotein P concen-
trations during the entire intervention period.
The statistical analyses were carried out using SAS
(release 9.4, SAS Institute, Inc., Cary, NC, USA) and the
procedure general linear model (GLM).
For all tests, a P value less than 0.05 was considered
statistically significant.
Results
We evaluated the effect of four functional polymorphisms
in GPX1, GPX4, and SELENOP on erythrocyte GPX
enzyme activity, whole blood selenium, and plasma sele-
noprotein P concentrations after consumption of 1000 g
fish and mussels per week for 26 consecutive weeks
(~ 50 μg selenium/day) in volunteer participants [28]. Fur-
thermore, we evaluated the effect of the intervention on
erythrocyte GPX enzyme activity.
Baseline characteristics of all participants including the
control group are presented in Table 1 as published previ-
ously [28], except for GPX enzyme activity measurements,
which have not been published previously. None of the
baseline variables differed between the two groups
(Table 1) or according to genotype (results not shown).
The genotype distributions of the studied polymorphisms
were in Hardy–Weinberg equilibrium (results not shown).
In Table 2, changes in erythrocyte GPX enzyme activ-
ity measurements within groups (intervention and
control) and differences between group changes are
illustrated. There were no statistically significant differ-
ences in erythrocyte GPX enzyme activity changes
between the intervention and control groups after,
neither 13 nor 26 weeks (Table 2).
In Table 3, the associations between mean erythrocyte
GPX enzyme activity, concentrations of whole blood selen-
ium and plasma selenoprotein P, and the studied polymor-
phisms, and within-subject effects between genotype and
time for the intervention group, are shown. A difference in
mean GPX enzyme activity at baseline was found for the
GPX1/rs1050450 polymorphism among participants who
were randomized to the intervention (P = 0.044). This dif-
ference in enzyme activity persisted after 13 and 26 weeks’
intervention, resulting in no statistically significant differ-
ence in response to the increased selenium intake between
genotypes. Mean GPX enzyme activity at baseline among
CC homozygotes was 104.1 and 84.0 U/g Hb among vari-
ant T-allele carriers (intervention group only—results not
shown). There was no interaction between any of the stud-
ied polymorphisms and whole blood selenium or plasma
selenoprotein P concentrations (Table 3). However, there
was a statistically significant difference of − 4.68 ng/mL
(95% CI − 8.49, − 0.871) between mean concentration of
plasma selenoprotein P at week 26 for variant T-allele and
CC homozygotes of the SELENOP/rs3877899 polymorph-
ism (Table 3). A mean difference in whole blood selenium
for the SELENOP/rs3877899 polymorphism was also seen;
however, this association was not statistically significant
(difference between means − 5.76 (95% CI − 12.5, 1.01).
Results for the control group are presented in
Additional file 2. None of the polymorphisms among
participants in the control group differed for either of the
outcome measures as expected.
In order to elucidate whether these differences in sele-
noprotein P and whole blood selenium concentrations
were due to chance or an effect of the intervention, we ex-
amined the association between the SELENOP/rs3877899
polymorphism and whole blood selenium and selenopro-
tein P concentrations, respectively, with the control group
included in the model (Figs. 1 and 2). After 26 weeks, the
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difference in whole blood selenium mean concentrations
between CC homozygotes and T-allele carriers was only
borderline statistically significant (P = 0.088) (Fig. 1),
whereas the mean difference in selenoprotein P concen-
trations between CC homozygotes and T-allele carriers of
the SELENOP/rs3877899 polymorphism was still statisti-
cally significant (P = 0.048) (Fig. 2).
We also tested whether sex, age, or BMI modified the
effect on the intervention for the studied polymor-
phisms, but we did not find any sign of such effect
modification (results not shown).
Discussion
The present study showed that CC homozygotes of the
SELENOP/rs3877899 polymorphism who consumed
1000 g fish and mussels per week for 26 consecutive
weeks had higher levels of both selenoprotein P and
whole blood selenium compared to fish and mussel con-
suming variant T-allele carriers and the control group
although the effect in whole blood selenium concentra-
tion was not statistically significant.
To our knowledge, this is the first study investigating
the effect of SELENOP and GPX polymorphisms after in-
gestion of high selenium content foods in a controlled
randomized trial. The SELGEN study [19] examined the
effect on plasma selenium and selenoprotein P concen-
trations of the same SELENOP polymorphisms as in the
present study before and after selenium supplementation
in a UK population also known to be low in selenium
status. Mean baseline plasma selenium concentrations in
the two studies were comparable (1.15 μmol/l corre-
sponding to 90.8 ng/mL in the SELGEN study and
85.8 ng/mL in the present study). The two investigated
SELENOP polymorphisms significantly affected plasma
selenium concentration after 6 weeks of supplementa-
tion with 100 μg selenium/day as sodium selenite [19].
The authors noted that the effect was strongest among
participants with a BMI exceeding 30 where SELENOP/
rs3877899 CC homozygotes (referred to as GG in [19])
and variant A-allele carriers of SELENOP/rs7579
responded better to selenium supplementation com-
pared to carriers of the variant T-allele (referred to as
A-allele in [19]) and GG homozygotes, respectively. The
same study reported a statistically significant increase in
plasma selenoprotein P concentration following selen-
ium supplementation and gender-specific differences in
Table 1 Baseline characteristics of the participants presented as
either number (%) or median value (5th–95th percentiles)
Variable MAF (%) Intervention group
(n = 49)
Control group
(n = 45)
Women 21 (43%) 19 (42%)
Men 28 (57%) 26 (58%)
Age, years 61 (51–72) 59 (51–73)
BMI, kg/m2 26.3 (21.0–31.1) 25.2 (20.3–32.5)
Whole blood
selenium, ng/mL
113.5 (91.3–147.4) 114.6 (96.6–136.0)1
Plasma selenoprotein
P, ng selenium/mL
51.4 (35.0–63.9)2 51.4 (35.4–65.7)3
Plasma selenium,
ng/mL
84.7 (67.8–106.5)2 86.4 (70.5–103.3)3
Erythrocyte GPX
enzyme activity,
U/g Hb
86 (57–153)4 84 (54–156)5
GPX1/rs1050450 29.8
CC 23 (47%) 22 (49%)
CT 22 (45%) 20 (44%)
TT 4 (8%) 3 (7%)
GPX4/rs713041 37.8
CC 16 (33%) 17 (38%)
CT 25 (51%) 26 (58%)
TT 8 (16%) 2 (4%)
SELENOP/rs3877899 19.1
CC 30 (61%) 30 (67%)
CT 18 (37%) 14 (31%)
TT 1 (2%) 1 (2%)
SELENOP/rs7579 30.3
GG 24 (49%) 19 (42%)
GA 22 (45%) 23 (51%)
AA 3 (6%) 3 (7%)
Part of this table has been published in [28]. MAF, minor allele frequency for
the studied population (n = 94). 1n = 44 due to exclusion of outlying values (n
= 1), all whole blood and plasma selenium and selenoprotein P concentrations
for this person were excluded; 2n = 46 due to errors in the laboratory
measures (n = 3), all plasma selenoprotein P concentrations and the plasma
selenium concentration analyzed only at baseline were excluded for these
persons; 3n = 42 due to errors in the laboratory measures (n = 2), all plasma
selenoprotein P concentrations and the plasma selenium concentration
analyzed only at baseline were excluded for these persons, and due to
exclusion of outlying values (n = 1). 4n = 44 since GPX activity was not
analyzed on persons having only baseline levels measured (n = 1). 5n = 41
since GPX activity was not analyzed on persons having only baseline levels
measured (n = 8)
Table 2 Changes within groups and differences between group changes in erythrocyte GPX enzyme activities
Mean change within group, log (U/g Hb) (95% CI)a Difference between group mean change, log (U/g Hb) (95% CI)*
N Weeks 0–13 n Weeks 0–26 N Weeks 0–26
Intervention 41 0.0332 (0.0160, 0.0503) 41 0.0461 (0.0239, 0.0684) 85 0.0263 (− 0.00498, 0.0577)
Control 44 0.0169 (0.000278, 0.0334) 44 0.0198 (− 0.00221, 0.0418)
aAdjusted for baseline levels of GPX enzyme activity
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Table 3 Association between mean concentrations of erythrocyte GPX enzyme activity, whole blood selenium, and selenoprotein P
in relation to the studied polymorphisms, and within-subject effects between genotype and time in the intervention group
Erythrocyte GPX enzyme activity, log (U/g Hb)
SNP n Baseline 13 weeksc 26 weeksc P value for interaction
between genotype
and timeDifference between
means (95% CI)
P value Difference between
means (95% CI)
P value Difference between means
(95% CI)
P value
GPX1/rs1050450
CC 20 − 0.224 (− 0.442,
− 0.00638)
0.044 0.0299 (− 0.00981,
0.0696)
0.14 − 0.00585 (− 0.06278,
0.0511)
0.84 0.085
CT +
TT
21
GPX4/rs713041
CC 15 0.129 (− 0.105,
0.364)
0.27 − 0.00532 (− 0.0462,
0.0355)
0.79 − 0.0143 (− 0.0711, 0.0424) 0.61 0.79
CT +
TT
26
SELENOP/rs3877899
CC 25 − 0.0228 (− 0.258,
0.212)
0.85 − 0.00617 (− 0.0459,
0.0335)
0.75 0.0145 (− 0.0407,
0.0697)
0.60 0.70
CT +
TT
16
SELENOP/rs7579
GG 22 − 0.0278 (− 0.258,
0.202)
0.81 − 0.0134 (− 0.0521,
0.0252)
0.49 − 0.0143 (− 0.0683, 0.0397) 0.60 0.81
GA +
AA
19
Whole blood selenium, ng/mL
SNP n* Baseline 13 weeksd 26 weeksd P value for interaction between
genotype and time
Difference between
means (95% CI)
P value Difference between
means (95% CI)
P value Difference between
means (95% CI)
P value
GPX1/rs1050450
CC 23 3.20 (− 5.46, 11.9) 0.46 − 0.989 (−7.89, 5.91) 0.77 − 1.24 (− 8.11, 5.63) 0.72 0.83
CT +
TT
26
GPX4/rs713041
CC 16 4.85 (− 4.32, 14.0) 0.29 − 2.76 (− 9.91, 4.38) 0.44 − 1.77 (− 8.93, 5.39) 0.62 0.54
CT +
TT
33
SELENOP/rs3877899
CC 30 0.989 (− 7.93, 9.91) 0.82 0.675 (− 6.37, 7.72) 0.85 − 5.76 (− 12.5, 1.01) 0.093 0.13
CT +
TT
19
SELENOP/rs7579
GG 24 4.44 (− 4.16, 13.0) 0.30 − 4.04 (− 10.9, 2.80) 0.24 1.60 (− 5.32, 8.53) 0.64 0.23
GA +
AA
25
Selenoprotein P, ng/mL
SNP nb Baseline 13 weekse 26 weekse P value for interaction between
genotype and time
Difference between
means (95% CI)
P value Difference between
means (95% CI)
P value Difference between
means (95% CI)
P value
GPX1/rs1050450
CC 21 4.17 (− 0.51, 8.85) 0.080 − 1.17 (− 5.38, 3.04) 0.58 − 2.56 (− 6.60, 1.47) 0.21 0.071
CT +
TT
25
GPX4/rs713041
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baseline concentrations and post-supplementation with
SELENOP/rs3877899 and SELENOP/rs7579, respectively.
Lower baseline concentration of plasma selenoprotein P
was measured in women who were heterozygous T-allele
carriers of the SELENOP/rs3877899 polymorphism com-
pared to men with corresponding genotype, while the op-
posite applied for CC homozygotes. Among carriers of the
SELENOP/rs7579 variant A-allele, men had higher plasma
selenoprotein P concentrations post-supplementation
compared to women. We were not able to reproduce the
findings on gender and BMI which could be due to a lack
of power to study gene-environment interactions in the
present study given the relatively small sample size. Our
study differs from the SELGEN intervention in several
ways which might contribute to the different findings.
Besides a longer study period (26 weeks compared to
6 weeks in the SELGEN study), different sources of selen-
ium and dosage levels were used in the interventions. We
supplemented with a dietary source of selenium, while sel-
enite was used in the SELGEN study, and at a dosage level
that was half the one given by Méplan et al. [19].
Compared to inorganic selenium, organic selenium
compounds, such as selenomethionine present in fish and
mussels, are non-specifically incorporated into the general
protein pool, leaving a smaller part of the absorbed selen-
ium readily available for biosynthesis of selenoproteins.
However, it is not clear whether this had an impact on the
results, given the long supplementation period and the
relatively high bioavailability of selenium from fish which
has been reported to be between 56 and 90% [11, 12, 38].
Table 3 Association between mean concentrations of erythrocyte GPX enzyme activity, whole blood selenium, and selenoprotein P
in relation to the studied polymorphisms, and within-subject effects between genotype and time in the intervention group
(Continued)
Erythrocyte GPX enzyme activity, log (U/g Hb)
CC 16 3.49 (− 1.47, 8.45) 0.16 0.801 (− 3.41, 5.01) 0.70 − 1.17 (− 5.32, 2.97) 0.57 0.48
CT +
TT
30
SELENOP/rs3877899
CC 28 − 2.33 (− 7.23, 2.57) 0.34 − 2.43 (− 6.53, 1.67) 0.24 − 4.68 (− 8.49, − 0.871) 0.018 0.33
CT +
TT
18
SELENOP/rs7579
GG 23 2.16 (− 2.63, 6.94) 0.37 1.72 (− 2.35, 5.79) 0.40 − 0.630 (− 4.66, 3.40) 0.75 0.79
GA +
AA
23
a13 and 26 weeks’ measurements only included 41 participants due to discontinuation of intervention
b13 and 26 weeks’ measurements only included 38 participants due to discontinuation of intervention
cAdjusted for baseline levels of erythrocyte GPX enzyme activity
dAdjusted for baseline levels of whole blood selenium
eAdjusted for baseline levels of selenoprotein P
Fig. 1 Association between mean concentrations of whole blood selenium and the SELENOP/rs3877899 polymorphism. Mean concentrations of
whole blood selenium ± SD for the intervention and control group estimated by linear multiple regression adjusted for baseline level of whole
blood selenium. P values for difference in mean whole blood selenium concentrations at week 26 for genotype effect within the intervention
group (*) and within the control group (**), respectively, are illustrated
Kopp et al. Genes & Nutrition  (2018) 13:20 Page 7 of 10
Increasing the intake of selenium with fish and mussels
did not affect erythrocyte GPX enzyme activity, suggesting
that this selenoprotein was maximally expressed prior to
supplementation. This is consistent with previous results,
showing that the antioxidant enzyme GPX is saturated at
blood selenium concentrations around 100 ng/mL [27,
46]. When stratifying the data according to genotype, in
line with previous findings [34], carriers of the variant
GPX1 allele had significantly lower erythrocyte GPX activ-
ity compared to CC homocygotes. A compromised anti-
oxidant defense may lead to increased susceptibility to
oxidative stress and DNA damage [25].
The increase in selenoprotein P concentration in the
control group from week 13 to week 26 is unexpected
and is difficult to explain (Fig. 2). This has been dis-
cussed in more detail in the main paper that evaluated
the intervention effect on blood selenium status [28].
Strengths and limitations of the overall study design
were thoroughly described by Outzen et al. [28]. Shortly,
the strengths of the study are the design with the
randomization procedure, which ensure evenly distribu-
tion of confounders, the restrictive inclusion and exclu-
sion criteria, and the long-term duration of the
intervention combined with the high compliance. Limi-
tations include lack of blinding and that participants
were non-fasting at blood sampling. However, we based
our results on whole blood which has been shown to
reflect the long-term selenium status [1, 17] as opposed
to plasma selenium, which has a short half-life [5]. With
regard to the lack of blinding, this is not expected to in-
fluence on this study since we mainly studied the effect
of genetic variation in the intervention group. We are
well aware of the present study being underpowered due
to the small sample size. Nevertheless, our study is in ac-
cordance with the SELGEN study, and we are therefore
able to support the notion that variation in the SELE-
NOP gene affects selenium biomarker concentration
after intake of both a selenium dietary supplement and
food with a high content of selenium.
Conclusion
Taken together, our study indicates that genetically
determined variation in SELENOP leads to different
responses in expression of selenoproteins following
consumption of selenium-rich foods. This emphasizes
the importance of taking individual aspects such as
genotypes into consideration when assessing risk in
public health recommendations, since they may affect
selenium metabolism and response to selenium intake
and thereby enable a more personalized approach to
micronutrient requirements.
Additional files
Additional file 1: Flow chart of study participants as previously
published [28]. (DOCX 37 kb)
Additional file 2: Association between mean concentrations of
erythrocyte GPX enzyme activity, whole blood selenium and
selenoprotein P in relation to the studied polymorphisms, and
within-subject effects between genotype and time in the control
group. (DOCX 24 kb)
Abbreviations
BMI: Body mass index; GPX: Glutathione peroxidases; SNP: Single nucleotide
polymorphism
Acknowledgements
The authors thank Lene Svensson and Annette Landin (Technical University
of Denmark, National Food Institute) for technical assistance with
determining GPX enzyme activity and DNA extraction and Erik Huusfeldt
Larsen for performing plasma selenoprotein P, plasma selenium, and whole
blood selenium measurements.
Fig. 2 Association between mean concentrations of selenoprotein P and the SELENOP/rs3877899 polymorphism. Mean concentrations of
selenoprotein P ± SD for the intervention and control group estimated by linear multiple regression adjusted for baseline level of selenoprotein
P. P values for difference in mean selenoprotein P concentrations at week 26 for genotype effect within the intervention group (*) and within the
control group (**), respectively, are illustrated
Kopp et al. Genes & Nutrition  (2018) 13:20 Page 8 of 10
Funding
The dietary intervention study was supported by funds from the Bjarne
Saxhof Foundation. The Foundation had no influence on the design and
conduct of the study, management, analysis, and interpretation of the data
or preparation of the manuscript.
Availability of data and materials
The datasets used for analysis during the current study are not publicly
available due to existing Danish data protection law, but available from the
corresponding author on reasonable request.
Authors’ contributions
TIK, MO, GRH, and UV conceived the study. TIK extracted DNA, genotyped
the participants, analyzed the data, and wrote the first draft of the
manuscript. MO and AO designed and conducted the randomized
intervention study. GRH analyzed GPX enzyme activities and participated in
writing the first draft of the manuscript. All authors have contributed to the
interpretation of data, critically revised the manuscript for important
intellectual content, and approved the final manuscript.
Ethics approval and consent to participate
The study was approved by the Danish Regional Committee on Biomedical
Research Ethics for the Capital Region of Denmark (H-2-2010-033) in
accordance with the Helsinki declaration. It was also approved by the Danish
Data Protection Agency (2010-41-5111). All participants were given oral and
written information about the study; written informed consent was obtained
from all participants included in the study. This study is registered at http://
www.clinicaltrials.gov as DCS-53227244.
Consent for publication
Not applicable.
Competing interests
The authors declare that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1National Food Institute, Technical University of Denmark, Kemitorvet,
Building 202, 2800 Kgs Lyngby, Denmark. 2Danish Cancer Society Research
Center, Strandboulevarden 49, 2100 Copenhagen Ø, Denmark. 3The Danish
Multiple Sclerosis Registry, Copenhagen University Hospital, Rigshospitalet,
Blegdamsvej 9, 2100 Copenhagen Ø, Denmark. 4National Research Centre for
the Working Environment, Lersø Parkallé 105, 2100 Copenhagen Ø, Denmark.
5The Danish Multiple Sclerosis Center, Department of Neurology, The Danish
Multiple Sclerosis Registry, Section 7801, Rigshospitalet, Blegdamsvej 9, 2100
Copenhagen Ø, Denmark.
Received: 5 March 2018 Accepted: 11 June 2018
References
1. Ashton K, Hooper L, Harvey LJ, et al. Methods of assessment of selenium
status in humans: a systematic review. Am J Clin Nutr. 2009;89:2025S–39S.
https://doi.org/10.3945/ajcn.2009.27230F.
2. Bermano G, Arthur JR, Hesketh JE. Role of the 3′ untranslated region in the
regulation of cytosolic glutathione peroxidase and phospholipid-
hydroperoxide glutathione peroxidase gene expression by selenium supply.
Biochem J. 1996;320(3):891–5.
3. Blein S, Berndt S, Joshi AD, et al. Factors associated with oxidative stress and
cancer risk in the Breast and Prostate Cancer Cohort Consortium. Free Radic
Res. 2014;48:380–6. https://doi.org/10.3109/10715762.2013.875168.
4. Brigelius-Flohé R, Müller C, Menard J, et al. Functions of GI-GPx: lessons from
selenium-dependent expression and intracellular localization. BioFactors.
2001;14:101–6. https://doi.org/10.1002/biof.5520140114.
5. Bügel S, Larsen EH, Sloth JJ, et al. Absorption, excretion, and retention of
selenium from a high selenium yeast in men with a high intake of selenium.
Food Nutr Res. 2008;52:1642. https://doi.org/10.3402/fnr.v52i0.1642.
6. Combs GF Jr, Watts JC, Jackson MI, et al. Determinants of selenium status in
healthy adults. Nutr J. 2011;10:75. https://doi.org/10.1186/1475-2891-10-75.
7. Cooper ML, Adami H-O, Grönberg H, et al. Interaction between single
nucleotide polymorphisms in selenoprotein P and mitochondrial superoxide
dismutase determines prostate cancer risk. Cancer Res. 2008;68:10171–7.
https://doi.org/10.1158/0008-5472.CAN-08-1827.
8. Cox DG, Tamimi RM, Hunter DJ. Gene x Gene interaction between MnSOD
and GPX-1 and breast cancer risk: a nested case-control study. BMC Cancer.
2006;6:217. https://doi.org/10.1186/1471-2407-6-217.
9. Fairweather-Tait SJ, Bao Y, Broadley MR, et al. Selenium in human health
and disease. Antioxid redox signal. 2011;14:1337–83. https://doi.org/10.1089/
ars.2010.3275.
10. Forsberg L, De Faire U, Morgenstern R. Low yield of polymorphisms
from EST blast searching: analysis of genes related to oxidative stress
and verification of the P197L polymorphism in GPX1. Hum Mutat. 1999;
13:294–300. https://doi.org/10.1002/(SICI)1098-1004(1999)13:4<294::AID-
HUMU6>3.0.CO;2-5.
11. Fox TE, Atherton C, Dainty JR, et al. Absorption of selenium from
wheat, garlic, and cod intrinsically labeled with Se-77 and Se-82 stable
isotopes. Int J Vitam Nutr Res. 2005;75:179–86. https://doi.org/10.1024/
0300-9831.75.3.179.
12. Fox TE, Van den Heuvel EGHM, Atherton CA, et al. Bioavailability of
selenium from fish, yeast and selenate: a comparative study in humans
using stable isotopes. Eur J Clin Nutr. 2004;58:343–9. https://doi.org/10.1038/
sj.ejcn.1601787.
13. Geybels MS, van den Brandt PA, Schouten LJ, et al. Selenoprotein gene
variants, toenail selenium levels, and risk for advanced prostate cancer. J
Natl Cancer Inst. 2014;106:dju003. https://doi.org/10.1093/jnci/dju003.
14. Hurst R, Collings R, Harvey LJ, et al. EURRECA—estimating selenium
requirements for deriving dietary reference values. Crit Rev Food Sci Nutr.
2013;53:1077–96. https://doi.org/10.1080/10408398.2012.742861.
15. J a N, Batista BL, Rodrigues JL, et al. A simple method based on Icp-Ms for
estimation of background levels of arsenic, cadmium, copper, manganese,
nickel, lead, and selenium in blood of the Brazilian population. J Toxicol
Environ Heal Part A. 2010;73:878–87. https://doi.org/10.1080/
15287391003744807.
16. Karunasinghe N, Han DY, Zhu S, et al. Serum selenium and single-
nucleotide polymorphisms in genes for selenoproteins: relationship to
markers of oxidative stress in men from Auckland, New Zealand. Genes
Nutr. 2012;7:179–90. https://doi.org/10.1007/s12263-011-0259-1.
17. Longnecker MP, Stram DO, Taylor PR, et al. Use of selenium concentration
in whole blood, serum, toenails, or urine as a surrogate measure of
selenium intake. Epidemiology. 1996;7:384–90. https://doi.org/10.1097/
00001648-199607000-00008.
18. Majolo F, de Oliveira Paludo FJ, Ponzoni A, et al. Effect of 593C> T GPx1
SNP alone and in synergy with 47C> T SOD2 SNP on the outcome of
critically ill patients. Cytokine. 2015;71:312–7. https://doi.org/10.1016/j.cyto.
2014.10.020.
19. Méplan C, Crosley LK, Nicol F, et al. Genetic polymorphisms in the human
selenoprotein P gene determine the response of selenoprotein markers to
selenium supplementation in a gender-specific manner (the SELGEN study).
FASEB J. 2007;21:3063–74.
20. Meplan C, Crosley LK, Nicol F, et al. Functional effects of a common single-
nucleotide polymorphism (GPX4c718t) in the glutathione peroxidase 4
gene: interaction with sex. Am J Clin Nutr. 2008;87:1019–27.
21. Méplan C, Dragsted LO, Ravn-Haren G, et al. Association between
polymorphisms in glutathione peroxidase and selenoprotein P genes,
glutathione peroxidase activity, HRT use and breast cancer risk. PLoS One.
2013;8:e73316. https://doi.org/10.1371/journal.pone.0073316.
22. Meplan C, Hughes DJ, Pardini B, et al. Genetic variants in selenoprotein
genes increase risk of colorectal cancer. Carcinogenesis. 2010;31:1074–9.
https://doi.org/10.1093/carcin/bgq076.
23. Méplan C, Nicol F, Burtle BT, et al. Relative abundance of selenoprotein P
isoforms in human plasma depends on genotype, se intake, and cancer
status. Antioxid Redox Signal. 2009;11:2631–40. https://doi.org/10.1089/ars.
2009.2533.
24. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for
extracting DNA from human nucleated cells. Nucleic Acids Res.
1988;16:1215.
25. Miranda-Vilela AL, Alves PC, Akimoto AK, et al. Gene polymorphisms against
DNA damage induced by hydrogen peroxide in leukocytes of healthy
Kopp et al. Genes & Nutrition  (2018) 13:20 Page 9 of 10
humans through comet assay: a quasi-experimental study. Environ Health.
2010;9:21. https://doi.org/10.1186/1476-069X-9-21.
26. Nemoto M, Nishimura R, Sasaki T, et al. Genetic association of glutathione
peroxidase-1 with coronary artery calcification in type 2 diabetes: a case
control study with multi-slice computed tomography. Cardiovasc Diabetol.
2007;6:23. https://doi.org/10.1186/1475-2840-6-23.
27. Nève J. Methods in determination of selenium states. J Trace Elem
Electrolytes Health Dis. 1991;5:1–17.
28. Outzen M, Tjønneland A, Larsen EH, et al. The effect on selenium
concentrations of a randomized intervention with fish and mussels in a
population with relatively low habitual dietary selenium intake. Nutrients.
2015a;7:608–24. https://doi.org/10.3390/nu7010608.
29. Outzen M, Tjønneland A, Larsen EH, et al. Effect of increased intake of fish
and mussels on exposure to toxic trace elements in a healthy, middle-aged
population. Food Addit Contam Part A. 2015b;32:1858–66. https://doi.org/
10.1080/19440049.2015.1072878.
30. Papp LV, Lu J, Holmgren A, Khanna KK. From selenium to selenoproteins:
synthesis, identity, and their role in human health. Antioxid Redox Signal.
2007;9:775–806. https://doi.org/10.1089/ars.2007.1528.
31. Raaschou-Nielsen O, Soerensen M, Hansen RDRD, et al. GPX1 Pro198Leu
polymorphism, interactions with smoking and alcohol consumption, and
risk for lung cancer. Cancer Lett. 2007;247:293–300. https://doi.org/10.1016/j.
canlet.2006.05.006.
32. Ravn-Haren G, Bügel S, Krath BN, et al. A short-term intervention trial with
selenate, selenium-enriched yeast and selenium-enriched milk: effects on
oxidative defence regulation. Br J Nutr. 2008a;99(4):883–92. https://doi.org/
10.1017/S0007114507825153.
33. Ravn-Haren G, Krath BN, Overvad K, et al. Effect of long-term selenium yeast
intervention on activity and gene expression of antioxidant and xenobiotic
metabolising enzymes in healthy elderly volunteers from the Danish
Prevention of Cancer by Intervention by Selenium (PRECISE) pilot study. Br J
Nutr. 2008b;99:1190–8. https://doi.org/10.1017/S0007114507882948.
34. Ravn-Haren G, Olsen A, Tjonneland A, et al. Associations between GPX1
Pro198Leu polymorphism, erythrocyte GPX activity, alcohol consumption and
breast cancer risk in a prospective cohort study. Carcinogenesis. 2006;27:820–5.
35. Rayman MP. Food-chain selenium and human health: emphasis on intake.
Br J Nutr. 2008;100(2):254–68. https://doi.org/10.1017/S0007114508939830.
36. Rayman MP. Selenoproteins and human health: insights from
epidemiological data. Biochim Biophys Acta - Gen Subj. 2009;1790:1533–40.
37. Rayman MP. Selenium and human health. Lancet. 2012;379:1256–68.
38. Robinson MF, Rea HM, Friend GM, et al. On supplementing the selenium intake
of New Zealanders. 2. Prolonged metabolic experiments with daily supplements
of selenomethionine, selenite and fish. Br J Nutr. 1978;39:589–600.
39. Rosenberger A, Illig T, Korb K, et al. Do genetic factors protect for early
onset lung cancer? A case control study before the age of 50 years. BMC
Cancer. 2008;8:60. https://doi.org/10.1186/1471-2407-8-60.
40. Saito Y, Sato N, Hirashima M, et al. Domain structure of bi-functional
selenoprotein P. Biochem J. 2004;381:841–6. https://doi.org/10.1042/
BJ20040328.
41. Saxholt E, Christensen AT, Møller A, et al (2008) Danish Food Composition
Databank, revision 7. In: Dep. Nutr. Natl. Food Institute, Tech. Univ. Denmark.
http://www.foodcomp.dk/
42. Soerensen M, Christensen K, Stevnsner T, Christiansen L. The Mn-superoxide
dismutase single nucleotide polymorphism rs4880 and the glutathione
peroxidase 1 single nucleotide polymorphism rs1050450 are associated with
aging and longevity in the oldest old. Mech Ageing Dev. 2009;130:308–14.
https://doi.org/10.1016/j.mad.2009.01.005.
43. Steinbrecher A, Méplan C, Hesketh J, et al. Effects of selenium status and
polymorphisms in selenoprotein genes on prostate cancer risk in a
prospective study of European men. Cancer Epidemiol Biomark Prev. 2010;
19:2958–68. https://doi.org/10.1158/1055-9965.EPI-10-0364.
44. Strauss E, Oszkinis G, Staniszewski R. SEPP1 gene variants and abdominal
aortic aneurysm: gene association in relation to metabolic risk factors and
peripheral arterial disease coexistence. Sci Rep. 2014;4:7061. https://doi.org/
10.1038/srep07061.
45. Tang TS, Prior SL, Li KW, et al. Association between the rs1050450 glutathione
peroxidase-1 (C > T) gene variant and peripheral neuropathy in two
independent samples of subjects with diabetes mellitus. Nutr Metab
Cardiovasc Dis. 2012;22:417–25. https://doi.org/10.1016/j.numecd.2010.08.001.
46. Thomson CD. Assessment of requirements for selenium and adequacy of
selenium status: a review. Eur J Clin Nutr. 2004;58:391–402. https://doi.org/
10.1038/sj.ejcn.1601800.
47. Udler M, Maia AT, Cebrian A, et al. Common germline genetic variation in
antioxidant defense genes and survival after diagnosis of breast cancer. J
Clin Oncol. 2007;25:3015–23.
48. Villette S, Kyle JAM, Brown KM, et al. A novel single nucleotide
polymorphism in the 3′ untranslated region of human glutathione
peroxidase 4 influences lipoxygenase metabolism. Blood Cells Mol Dis. 2002;
29:174–8. https://doi.org/10.1006/bcmd.2002.0556.
49. Wheeler CR, Salzman JA, Elsayed NM, et al. Automated assays for
superoxide dismutase, catalase, glutathione peroxidase, and glutathione
reductase activity. Anal Biochem. 1990;184:193–9.
50. Ye H, Li X, Wang L, et al. Genetic associations with coronary heart disease:
meta-analyses of 12 candidate genetic variants. Gene. 2013;531:71–7.
https://doi.org/10.1016/j.gene.2013.07.029.
Kopp et al. Genes & Nutrition  (2018) 13:20 Page 10 of 10
